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Abstract
Background: Drugs that simultaneously target multiple proteins often improve efficacy, particularly in the treatment of
complex diseases such as cancers and central nervous system disorders. Many approaches have been proposed to
identify the potential targets of a drug. Recently, we have introduced Space-Related Pharmamotif (SRPmotif) method to
recognize the proteins that share similar binding environments. In addition, compounds with similar topology may
bind to similar proteins and have similar protein-compound interactions. However, few studies have focused on
exploring the relationships between binding environments and protein-compound interactions, which is important for
understanding molecular binding mechanisms and helpful to be used in discovering drug repurposing.
Results: In this study, we propose a new concept of “Homopharma”, combining similar binding environments and
protein-compound interaction profiles, to explore the molecular binding mechanisms and drug repurposing. A
Homopharma consists of a set of proteins which have the conserved binding environment and a set of
compounds that share similar structures and functional groups. These proteins and compounds present conserved
interactions and similar physicochemical properties. Therefore, these compounds are often able to inhibit the
proteins in a Homopharma. Our experimental results show that the proteins and compounds in a Homopharma
often have similar protein-compound interactions, comprising conserved specific residues and functional sites.
Based on the Homopharma concept, we selected four flavonoid derivatives and 32 human protein kinases for
enzymatic profiling. Among these 128 bioassays, the IC50 of 56 and 25 flavonoid-kinase inhibitions are less than 10
μM and 1 μM, respectively. Furthermore, these experimental results suggest that these flavonoids can be used as
anticancer compounds, such as oral and colorectal cancer drugs.
Conclusions: The experimental results show that the Homopharma is useful for identifying key binding
environments of proteins and compounds and discovering new inhibitory effects. We believe that the
Homopharma concept can have the potential for understanding molecular binding mechanisms and providing
new clues for drug development.
Background
Developing a new drug is difficult and takes on average of
13 years as well as US$1.8 billion [1]. Traditional
approaches for rational drug design used the “one gene,
one drug, one disease” paradigm to design exquisitely
selective ligands of a single disease target. For example,
gefitinib (trade name Iressa) and imatinib (trade name
Gleevec) have been developed by this strategy and used
for lung cancer and chronic myeloid leukemia, respec-
tively. However, many drugs have been indicated that they
can interact with more than one target protein [2-4].
Some unexpected efficacy can be linked to activity against
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additional targets, such as imatinib and PDGF receptor [5].
Previous work has identified that a drug interacts with 6
targets on average by analyzing a drug-target network con-
sisting of 802 drugs and 4,746 interactions [6]. Many stu-
dies also suggest that drug development on targeting
multiple proteins simultaneously can improve efficacy,
particularly in the treatment of complex diseases (e.g. can-
cer and central nervous system disorders) [7,8]. The strat-
egy of pharmaceutical research, defined as the specific
binding of a compound to two or more molecular targets,
has variously been termed “network-based” discovery,
“multi-targeted” drug design, “targeted polypharmacol-
ogy”, or “polypharmacology” [9-17].
One challenge of targeted polypharmacology is to
identify the molecular targets that bind the compound.
To recognize the proteins with similar binding sites of a
given protein sequence or structure, the computational
approaches of searching the protein sequence or struc-
ture databases are usually utilized [18-21]. As the num-
ber of protein structures is increasing, protein structures
have been proposed to analyze the structural motifs and
to describe the binding environments [22,23]. However,
most of these studies [24-28] search for similar local
structures or binding sites (active sites) based on only
one structural motif. Recently, we have introduced
Space-Related Pharmamotif (SRPmotif) method [29] to
identify pharma-interfaces (≥ 2 structural motifs) from a
set of proteins which share similar binding environ-
ments. A pharma-interface is consists of a set of spa-
tially discontinuous pharma-motifs which surround the
ligand-binding site. In addition, compounds with similar
topology would bind to the same or similar proteins and
have similar protein-compound interactions [3,4]. How-
ever, few studies focused on exploring the relationships
between binding environments and protein-compound
interactions. The atomic interactions between a com-
pound and a protein are important when a compound
target a protein. The combination of similar binding
environments and protein-compound interactions pro-
vides the opportunities to explore the molecular binding
mechanisms and is helpful for drug repurposing.
To address this issue, we proposed a new concept of
“Homopharma” to describe similar binding environments
and the relationships of interactions between proteins
and compounds. A Homopharma is a set of proteins
which have the conserved sub-binding environment at
the protein-compound interfaces and a set of compounds
with similar topology. Our results demonstrated that pro-
tein-compound complexes of a Homopharma perform
similar protein-compound interactions and comprise
conserved specific residues and important functional
sites. According to the Homopharma concept, four simi-
lar flavonoid derivatives were tested against 32 human
protein kinases using in vitro enzymatic profiling. The
experimental results identified that the IC50 values of 56
and 25 flavonoid-kinase inhibitions are less than 10 μM
and 1 μM, respectively. Some novel protein-compound
interactions also suggest that these flavonoids could be
used as anticancer compounds such as oral and colorec-
tal cancer drugs. These results show that the concept
Homopharma is not only useful for identifying potential
targets of compounds, but can also reveal the key binding
environment. Furthermore, it would be helpful for disco-
vering the new usages for existing drugs. We believe that
this approach can be further applied to understand mole-




In this study, we propose a new concept “Homopharma”
to describe similar binding environment and the relation-
ships of interactions between proteins and compounds.
Proteins sharing similar binding environments can usually
be targeted by a set of compound with similar topology.
We considered that a Homopharma comprises of a set of
proteins which have the conserved sub-binding environ-
ment at the protein-compound interfaces and a set of
compounds with similar topology. For a complex struc-
ture, the proteins with similar pharma-interfaces are first
recognized by SRPmotif. The complexes with significant
compound topology similarity are reserved. Then, the pro-
tein-compound interaction similarity scores are measured.
Consequently, the proteins and compounds which share
similar protein-compound interactions are considered as a
Homopharma. Figure 1 shows the detailed steps to iden-
tify a Homopharma from a given complex by the following
steps.
Step 1: Search candidates of a pharma-interface
SRPmotif is utilized to rapidly search potential targets
having similar pharma-interfaces (Figure 1A). A pharma-
interface can be described as follows: (1) a pharma-interface
is a conserved binding interface of multiple proteins which
share similar interfaces and are often inhibited by similar
compounds; (2) a pharma-interface consists of a set of spa-
tially discontinuous pharma-motifs; (3) a pharma-motif is a
short conserved peptide forming a specific sub-interface
with interacting residues and specific physico-chemical
properties. Each discontinuous pharma-motif of a query
complex is translated to 1D sequence with 23 structural
alphabets using  and a angles defined in the DSSP pro-
gram [30] and applied to search against Protein Data Bank
(PDB) [31] by 3D-BLAST [32,33]. The candidate structures
are then superimposed with the discontinuous pharma-
motifs of the query complex by DALI [34], which is a struc-
tural alignment tool based on contact similarity patterns.
The candidate protein-compound complexes of root-
mean-square deviation (RMSD) ≤ 3Å are reserved. All
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search parameters of SRPmotif are default. Accordingly, a
pharma-interface which consists of several pharma-motifs
is constructed based on the conserved binding interfaces.
The complexes of the pharma-interface are then used to
estimate the protein-compound interaction profile and to
evaluate interaction similarities.
Step 2: Calculate protein-compound interaction profiles
A compound would bind to proteins having similar
binding environments; as well as proteins often interact
with compounds of similar topology. These protein-
compound interactions provide the opportunities to
explore the molecular binding mechanisms. After identi-
fications of candidate complexes, similarities between all
crystal ligands of complexes are calculated by atom
pairs (AP) [35]. The structures whose crystal ligands
with significant topology similarity (≥ 0.6) to any com-
pound are reserved. To measure the similarity between
protein-compound interactions, a multiple protein
Figure 1 Overview of identification of Homopharma using serine/threonine-protein kinase Pim-1 and quercetin complex as query.
(A) Search similar pharma-interface candidates of serine/threonine-protein kinase Pim-1 and quercetin complex. (B) The candidates with bound
compounds and RMSD ≤ 3Å are used to generate multiple sequence alignment and the protein-compound interaction profile using iGEMDOCK.
The interaction profile is clustered into several Homopharma groups based on interaction similarity scores. (C) Some superimposed complex
structures of Homopharma 3. (D) The flavonoid derivative (JMY65) is tested against 32 selected protein kinases based on Homopharma concept.
Among 32 bioassays, the IC50 of 11 and 18 kinase-JMY65 interactions are less than 1 μM (red) and 10 μM (blue), respectively. The green and dark
denote the inhibition efficiency from high to low.
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sequence (or structure) alignment is required. In this
work, a multiple protein sequence alignment is utilized
and generated by the reserved structures and T-coffee
[36]. Finally, the protein-compound interaction profile
of candidate complexes is calculated based on iGEM-
DOCK [37]. Different interaction types (electrostatic,
hydrogen bonding, and van der Waals) and interactions
of main- and side-chain heavy atoms are considered
separately.
Step 3: Cluster interaction profiles using interaction
similarity
After estimations of the protein-compound interaction
profile, conserved interaction similarity scores between
protein-compound interactions are evaluated. To mea-
sure the interacting conservation, the conservation
weight of each position of multiple sequence alignment





where N is the number of compound members of the
pharma-interface and f ki is the number of interactions of
the residue in MSA position i interacting with com-
pounds with the interaction type k (i.e., electrostatic,
hydrogen bonding, and van der Waals). The interaction
similarity score between two protein-compound interac-















where Ai and Wi is the interaction and the conserva-
tion weight in position i of the MSA, respectively.
Consequently, the protein-compound interactions are
clustered by two-way hierarchical clustering. These
interactions are divided into several Homopharma
groups, which consist of similar binding environment,
compound topology and interactions.
Protein-ligand complex validation dataset
To verify the Homopharma concept, protein-compound
complexes were obtained from PDB. The complexes are
eliminated when compounds are metal ions, surface
compounds, cofactors, and small compounds (heavy
atoms < 6). Two protein-compound pairs are grouped
according to the same proteins or compounds. The pro-
tein-compound groups are filtered by number of com-
plexes below 50% of all possible protein-compound
combinations. Two groups which overlap with more
than 50% protein or compounds are merged. Finally,
176 protein-compound groups that contain 1,325 complex
structures including 672 proteins and 471 compounds are
used as validation dataset.
Results and discussion
Evaluations of compound similarity
A protein-compound complex having significant com-
pound similarity is considered as a candidate of a
Homopharma. In order to decide the threshold of com-
pound topology similarity, we collected 3,151 crystal
complex structures of 957 proteins. The distribution
demonstrates the relationships between percentage and
compound topology similarity (Figure S1A in Additional
file 1). The precision, recall, and f-measure values were
evaluated and the highest F-measure is at 0.36 when the
compound topology similarity is 0.6 as well as the preci-
sion value is over 0.4. For example, methotrexate
(MTX) is the first generation of dihydrofolate reductase
(DHFR) inhibitor; the values of compound similarity of
COP and DTM to MTX are 0.7 and 0.3, respectively
(Figure S1B in Additional file 1). The compound COP is
also the first generation of DHFR inhibitor and has simi-
lar topology to MTX; however, DTM is the second gen-
eration inhibitor and performs a different binding mode.
Another compound estrogen (EST) presents similar
results. The compound DES (similarity: 0.8) is the estro-
gen receptor agonist that present the same function
with EST, where RAL (similarity: 0.2) is just an estrogen
receptor antagonist.
Evaluations of interaction similarity
To evaluate the performance of interaction similarity, we
collected 176 protein-compound groups from PDB. Two
protein-compound pairs in the same groups are consid-
ered as positive pairs; otherwise, pairs are negative pairs.
We also evaluated the performance of identifying pro-
tein-compound pairs by protein similarity and com-
pound similarity. The thresholds of protein similarity
and compound similarity are BLAST e-value ≤ 10-10 and
topology similarity ≤ 0.6, respectively. Two pairs are
considered as similar interactions while their interaction
similarity is greater than 0.6. The receiver operating
characteristic (ROC) curves were estimated to compare
protein similarity, compound similarity and interaction
similarity (Figure 2). The results showed that interaction
similarity (red) provides better performance than protein
similarity (blue) and compound similarity (black).
Example analysis: thymidine kinase
The proteins and compounds in a Homopharma would
share conserved interactions and similar physicochem-
ical properties. Therefore, these compounds are often
able to inhibit these proteins in a Homopharma. Figure
3A shows that the pharma-interface and Homopharma
groups by using the thymidine kinase (TK) of Herpes
simplex virus and deoxythymidine (THM) complex
(PDB code: 1KIM, chain A) as the query complex. Due
to specific expression of herpes thymidine kinase (TK)
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in herpesvirus-infection cells, TK becomes an antiviral
target of current drugs, such as acyclovir and vidarabine.
The identified pharma-interface contains five conserved
pharma-motifs. Furthermore, the clustering of interac-
tion profiles demonstrates protein-compound interac-
tions can be separated into four Homopharma groups.
The complexes in a Homopharma present similar
binding modes and have the conserved interacting resi-
dues (Figures 3B and 3C). Moreover, the conserved
interacting residues of these Homopharma groups are
often related to ligand binding and catalytic residues.
For example, Figure 3B shows the superimposed struc-
tures of Homopharma 1 and conserved interacting resi-
dues (residue numbering of PDB code: 1OI3). Several
interacting residues (H58, E83, W88, and Y172) are
highly conserved in Homopharma 1. Residue E225 is
important to form hydrogen bonding that stabilizes the
LID region for TK catalytic reaction and H58L/M128F/
Y172F triple mutant has also been indicated that related
to the resistance of current anti-TK drugs, such as acy-
clovir [38]. The conserved interaction profiles are pre-
sented in Figure S2A in Additional file 1. However,
Homopharma 2 has different conserved interacting resi-
dues to Homopharma 1 (Figures 3C and S2B in Addi-
tional file 1). Residues H58, E83, W88, and Y172 are
also conserved in Homopharma 1 as well; however, the
specific conserved residue R222 of Homopharma 2
interacts with phosphate group of TK substrates [38].
Furthermore, Homopharma 3 and 4 also present differ-
ent binding environments (Figures S2C and S2D in
Additional file 1).
Example analysis: protein kinases and flavonoid
derivatives
Flavonoids are a class of plant secondary metabolites
and have more than 5,000 kinds of derivatives. Flavo-
noid derivatives have been crystallized within more than
300 protein complex structures, such as protein kinases.
Protein kinases play important roles in cell growth and
signal transduction [39,40]. Protein kinases are one of
the most important classes of drug targets, because the
deregulation of kinase functions is often implicated in
many diseases, such as cancers and neurological and
metabolic diseases [40-42]. Although protein kinases
share a highly conserved ATP binding environment;
however, identical kinase inhibitor has varied inhibitory
effects on different kinases [3,4]. Because protein kinases
are involved in many complex diseases, many flavonoid
derivatives whose biological activities are known on
kinases may be repositioned to potential candidates of
other diseases.
In this study, we use serine/threonine-protein kinase
Pim-1 (PIM1) and quercetin complex (PDB code: 2O3P,
chain A) to identify pharma-interface and Homopharma
groups. After recognitions of 975 protein-compound
complexes by four pharma-motifs, six Homopharma
groups are identified according to the interaction simi-
larity (Figures 4A and S3 in Additional file 1). Among
these groups, Homopharma 3 shows the highly con-
served interactions to DFG motif [43], which is the
Figure 2 The receiver operating characteristic curves of
different similarities. The receiver operating characteristic curves
using protein similarity (blue), compound similarity (black), and
protein-compound interaction similarity (red) based on 176 protein-
compound groups.
Figure 3 The pharma-interface and Homopharma groups of
thymidine kinase and deoxythymidine complex. (A) The
pharma-interface of thymidine kinase (TK) and deoxythymidine
(THM) complex consists of five pharma-motifs. The protein-
compound interactions were grouped into four Homopharma
groups based on interaction similarity scores. (B) The superimposed
structures of Homopharma 1 and conserved interacting residues
(residue numbering of PDB code: 1OI3). (C) The superimposed
structures of Homopharma 2 and conserved interacting residues
(residue numbering of PDB code: 1KIM).
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beginning of activation loop of kinase (Figure 4B). The
conformation of DFG motif is relevant to kinase activa-
tion and the conserved aspartic acid binds directly to
the magnesium ion cofactor orienting the g-phosphate
of ATP for transfer. Conserved interacting residues,
such as L108 and M109 (residue numbering of PDB
code: 3BV2), are involved in hinge motif, which interacts
with adenine of ATP. Most compounds of Homopharma
3 belong to Type II kinase inhibitors, which occupy the
ATP binding region and allosteric pocket exposed in the
kinase inactive conformations [44,45].
Homopharma 4 also performs the conserved interac-
tions to hinge motif (Figure 4C). However, these com-
pounds of Homopharma 4 belong to Type I kinase
inhibitors, which target kinases with active conformation
and directly compete with ATP binding. Furthermore,
compounds of Homopharma 2 are also Type I kinase
inhibitors, but have different topology and interacting
residues (Figure S3B in Additional file 1). These com-
pounds perform more interactions with residues of
C-lobe pocket. Previous study showed that the con-
served aspartic acid in C-loop is important in position-
ing the substrate hydroxyl for in-line nucleophilic attack
[46]. Similar observations can be found in other Homo-
pharma groups (Figure S3 in Additional file 1).
Kinase profiling experiment results
To examine the ability of Homopharma for discovering
novel potential targets, we selected quercetin and three
similar flavonoid derivatives to test potential target
kinases in Homopharma groups. Four selected flavonoid
derivatives were obtained from Toronto Research Che-
micals (Figure 5). Based on six Homopharma groups of
the PIM1-quercetin complex, test kinases were predicted
as potential targets by the following step: (1) four flavo-
noids were docked to these kinase structures of the
identified pharma-interface by iGEMDOCK; (2) interac-
tion profiles were analyzed from the docking poses that
have the lowest energy; (3) interaction similarity scores
were measured to the PIM1-quercetin complex; (4) the
kinases of the same Homopharma group have the prior-
ity with selection. Most kinases were selected from
Homopharma 2, 4, and 5. Furthermore, some kinases
which are either not considered potential targets or not
searched by pharma-interface were also collected. Even-
tually, 32 protein kinases were chosen (Table 1 and
Figure S4 in Additional file 1).
In vitro enzymatic profiling of the 32 member kinase
panel was performed at Reaction Biology Corporation
(www.reactionbiology.com, Malvern, PA) using the “Hot-
Spot” assay platform [3]. Each kinase activity assay was
performed in duplicate with inhibitor concentration of 10
μM and an ATP concentration of 10 μM. The experi-
mental results show that three similar flavonoids (querce-
tin, JMY51, and JMY65) have similar inhibitory effects on
the tested 32 kinases. The results indicate that kinases in
the same Homopharma group are inhibited by similar
compounds. Our results also discover novel interactions,
for example, JMY65 has SRC, LCK, and KIT inhibitory
activities (Figures 5C and 5E). Moreover, JMY65 could be
used to treat oral cancer because of its inhibitory effects
on AKT2, IGF1R, EGFR, and MAPK3 (Figures 5C and
5E), which are highly expressed in oral cancer cells.
Another compound JMY84 could also be used as drug
candidates of colorectal cancer due to its effects on
CHEK2, LIMK1, and FGFR1 (Figures 5D and 5E).
These 32 tested kinases were divided into two
Homopharma groups and the superimposed structures
of two groups are presented in Figure 6. Most kinases
of Homopharma A are inhibited by tested flavonoid
derivatives and have different interacting residues and
binding environments than Homopharma B. The loca-
tions of DFG motif are varied between these groups
(Figure 6A). The co-crystal compounds also suggest
the difference of binding environments. These results
showed that our approach could discover potential tar-
gets of a set of similar compounds based on Homo-
pharma group.
Conclusions
In this study, we propose a new concept of “Homo-
pharma”, combining similar binding environments and
protein-compound interaction profiles, to explore the
Figure 4 The pharma-interface and Homopharma groups of
serine/threonine-protein kinase Pim-1 and quercetin complex.
(A) The pharma-interface of serine/threonine-protein kinase Pim-1
(PIM1) and quercetin complex consists of four pharma-motifs. The
protein-compound interactions are grouped into six Homopharma
groups. (B) The superimposed structures of Homopharma 3 and
conserved interacting residues (residue numbering of PDB code:
3BV2). (C) The superimposed structures of Homopharma 4 and
conserved interacting residues (residue numbering of PDB code:
3GUB).
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Figure 5 The in vitro enzymatic profiling results. (A) Quercetin and its target kinases. (B) JMY51 and its target kinases. (C) JMY65 and its
target kinases. (D) JMY84 and its target kinases. The red and blue points mean the bioactivities are ≤ 1 μM and ≤ 10 μM, respectively. Kinome
tree representation is prepared using Kinome Mapper (http://www.reactionbiology.com/apps/kinome/mapper/LaunchKinome.htm). (E) The in
vitro enzymatic profiling results of 32 protein kinases and four flavonoid derivatives. The green and dark denote the inhibition efficiency from
high to low.








AKT2 AGC SK019 v-akt murine thymoma viral oncogene homolog 2
DMPK AGC SK111 dystrophia myotonica-protein kinase
PRKCA AGC SK303 protein kinase C, alpha
RPS6KA1 AGC SK338 ribosomal protein S6 kinase, 90kDa, polypeptide 1
CAMK2G CAMK SK060 calcium/calmodulin-dependent protein kinase (CaM kinase) II gamma
CAMK4 CAMK SK061 calcium/calmodulin-dependent protein kinase IV
CHEK1 CAMK SK078 CHK1 checkpoint homolog (S. pombe)
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molecular binding mechanisms and drug repurposing. A
Homopharma consists of a set of proteins sharing con-
served binding environment and a set of compounds
which have similar structures and functional groups. In
a Homopharma, the compounds are often able to inhibit
these proteins because their interactions and physico-
chemical properties are often consensus. Experimental
results show that protein-compound complexes of a
Homopharma often perform similar interactions in
which formed by conserved binding residues (protein
sites) and similar important functional groups (com-
pound sites). According to the Homopharma concept,
we successfully discovered 56 flavonoid-kinase inhibi-
tions (IC50 ≤ 10 μM) by in vitro enzymatic profiling.
Among these 56 inhibitions, the IC50 values of 25 bioas-
says are less than 1 μM and these flavonoids can be
considered as potential anticancer compounds. These
results show that Homopharma is not only useful to
identify potential targets of compounds, but also can
reveal the key binding environments. We believe that
the Homopharma concept is useful for understanding
molecular binding mechanisms and providing new
opportunities for drug repurposing.
Additional material
Additional file 1: Supplementary Figures
Table 1 List of 32 tested protein kinases for in vitro enzymatic profiling. (Continued)
CHEK2 CAMK SK079 CHK2 checkpoint homolog (S. pombe)
PIM1 CAMK SK291 pim-1 oncogene
CSNK1G1 CK1 SK647 casein kinase 1, gamma 1
VRK1 CK1 SK389 vaccinia related kinase 1
CDK6 CMGC SK071 cyclin-dependent kinase 6
CLK3 CMGC SK092 CDC-like kinase 3
CSNK2A1 CMGC SK088 casein kinase 2, alpha 1 polypeptide
MAPK10 CMGC SK190 mitogen-activated protein kinase 10
MAPK14 CMGC SK264 mitogen-activated protein kinase 14
MAPK3 CMGC SK134 mitogen-activated protein kinase 3
MAP2K1 STE SK217 mitogen-activated protein kinase kinase 1
STK10 STE SK426 serine/threonine kinase 10
STK24 STE SK246 serine/threonine kinase 24 (STE20 homolog, yeast)
EGFR TK SK118 epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog,
avian)
FGFR1 TK SK143 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome)
IGF1R TK SK174 insulin-like growth factor 1 receptor
INSR TK SK178 insulin receptor
KIT TK SK201 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
LCK TK SK206 lymphocyte-specific protein tyrosine kinase
SRC TK SK357 v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)
SYK TK SK363 spleen tyrosine kinase
ACVR1 TKL SK026 activin A receptor, type I
LIMK1 TKL SK412 LIM domain kinase 1
MAP3K7 TKL SK364 mitogen-activated protein kinase kinase kinase 7
RAF1 TKL SK324 v-raf-1 murine leukemia viral oncogene homolog 1
Figure 6 The superimposed structures and enzymatic profiling
results. (A) The 16 protein kinases inhibited by four flavonoids
(quercetin, JMY51, JMY65, and JMY84) are superimposed (residue
numbering of PDB code: 2O3P). Kinases and flavonoids are colored by
green and pink, respectively. (B) The structures of 16 protein kinases,
which are not inhibited by four flavonoids, are superimposed (residue
numbering of PDB code: 3OP5). Kinases are colored by blue.
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